Immunotherapy in first-line standard therapy significantly improves survival in metastatic or recurrent cervical cancer
byVall d'Hebron Institute of OncologyCredit: CC0 Public DomainPublished inThe Lancet, results of the randomized phase III BEATcc academic trial (ENGOT-Cx10/GEICO 68-C/JGOG1084/GOG-3030
Updated on: January 26,2024
10

Immunotherapy in first-line standard therapy significantly improves survival in metastatic or recurrent cervical cancer
byVall d'Hebron Institute of OncologyCredit: CC0 Public DomainPublished inThe Lancet, results of the randomized phase III BEATcc academic trial (ENGOT-Cx10/GEICO 68-C/JGOG1084/GOG-3030
Updated on:January 26,2024
10
